BassieNL schreef op 8 januari 2020 16:18:
Oke, het is even geleden: op 29/10/2018 heeft First Berlin een advies uitgebracht, onderbouwd door de volgende
verwachtingen die door het management van Pharming zijn afgegeven:
New Delivery methods. Clinical studies of these formulations are expected
to start later this year. Topline data are expected in 2020.
Pharming plans to start its own phase II study of Ruconest in CIN in Q1 2019
in preparation for a later pivotal phase III trial.
Pre-eclampsia. Management has indicated that the readout from a phase II trial could be available in Q3 2019.
Pompe Disease will begin in H1 2019.
Fabry’s Disease will take place from H2 2020.
Delayed Graft Function (DGF). Topline data are expected in 2020.
Pharming plans to start a phase I/II trial of Ruconest with hemorrhagic shock patients in 2020.